Drug Trial Radar · NCT05368974
The Treatment in Pregnancy for Hepatitis C ("TiP-HepC") Registry
Last checked: Nov 20, 2026Latest source record: Dec 18, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
100
Planned (sponsor's estimate)
Start
Feb 11, 2022
Primary completion
Jun 30, 2026
Study completion Dec 30, 2026
Sponsor
- Lead sponsor
- The Task Force for Global HealthAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Centers for Disease Control and Prevention
- First posted
- May 10, 2022
Design
- Study type
- Observational
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
Clinical interventions to reduce the risk of vertical transmission of hepatitis C virus (HCV) infection from mother to infant are highly limited. Direct-acting antiviral (DAA) medications have demonstrated excellent safety and efficacy in non-pregnant individuals, but there is a lack of data regarding the safety of these medications in pregnant women and the effectiveness of these medications in reducing mother-to-child transmission. Therefore, although HCV screening during pregnancy is now recommended in many countries, there is no approved treatment for HCV during pregnancy. An observational study is here proposed to assess outcomes of mother-infant pairs exposed to DAAs during pregnancy within a global clinical case registry. Data regarding the exposures and outcomes of mother-infant pairs exposed to DAAs during pregnancy will be solicited and collected from clinical providers, healthcare facilities, HCV treatment programs, and other clinical practices worldwide. Data will be shared and maintained within a secure database, and cumulative data will be analyzed at pre-determined six-month intervals. The primary outcome will be the number and proportion of mother-infant pairs with adverse pregnancy or birth outcomes. The results of this study will inform HCV treatment decisions by clinical providers and programs worldwide.
Conditions
- Hepatitis C
Interventions
Direct Acting AntiviralsDrug
Direct-acting antiviral exposure during documented pregnancy
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of adverse pregnancy outcomesTime frame: 1 year
- Number of adverse birth outcomesTime frame: 1 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The Taskforce for Global Health
Atlanta, Georgia · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.